Pediatrix Medical Group (NYSE:MD) Hits New 1-Year High – Should You Buy?

Pediatrix Medical Group, Inc. (NYSE:MD) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $13.02 and last traded at $13.01, with a volume of 44878 shares changing hands. The stock had previously closed at $12.86.

Analyst Upgrades and Downgrades

MD has been the topic of a number of research reports. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Jefferies Financial Group raised Pediatrix Medical Group from a “hold” rating to a “buy” rating and raised their target price for the stock from $8.00 to $14.00 in a research report on Thursday, September 26th. Finally, Truist Financial lifted their target price on Pediatrix Medical Group from $10.00 to $13.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $10.90.

Pediatrix Medical Group Stock Performance

The company’s 50-day moving average price is $11.44 and its two-hundred day moving average price is $9.29. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -4.24, a PEG ratio of 1.92 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.38 and a quick ratio of 1.38.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.03. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The business had revenue of $504.30 million for the quarter, compared to analysts’ expectations of $505.49 million. During the same quarter in the prior year, the firm posted $0.37 earnings per share. The business’s quarterly revenue was up .7% compared to the same quarter last year. On average, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.19 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the sale, the chief executive officer now owns 170,001 shares in the company, valued at $1,834,310.79. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares in the company, valued at $1,834,310.79. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO C Marc Richards sold 17,438 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $10.08, for a total value of $175,775.04. Following the transaction, the chief financial officer now directly owns 175,347 shares in the company, valued at approximately $1,767,497.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 68,100 shares of company stock valued at $701,889 over the last 90 days. Company insiders own 1.20% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new position in shares of Pediatrix Medical Group during the second quarter valued at about $31,000. Innealta Capital LLC bought a new position in Pediatrix Medical Group in the 2nd quarter valued at about $33,000. Nisa Investment Advisors LLC lifted its position in Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in Pediatrix Medical Group during the 2nd quarter valued at about $72,000. Finally, CWM LLC increased its holdings in Pediatrix Medical Group by 134.0% during the 3rd quarter. CWM LLC now owns 6,427 shares of the company’s stock worth $74,000 after purchasing an additional 3,681 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.